OKYO Pharma Ltd ADR Net Assets
OKYO Pharma Ltd ADR net assets. Based on the latest financial reports, OKYO Pharma Ltd ADR (OKYO) has net assets worth $12.34 Million USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($20.98 Million) and total liabilities ($8.64 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore OKYO Pharma Ltd ADR equity growth rate to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $12.34 Million |
| % of Total Assets | 58.81% |
| Annual Growth Rate | -4.35% |
| 5-Year Change | 318.51% |
| 10-Year Change | -55.14% |
| Growth Volatility | 79.95 |
Net Assets of OKYO Pharma Ltd ADR (2008–2026)
Net assets of OKYO Pharma Ltd ADR from 2008 to 2026. This chart illustrates how OKYO Pharma Ltd ADR's net assets have evolved over time, based on quarterly financial data. See net asset quality index of OKYO Pharma Ltd ADR to measure how much of total assets are equity-financed.
Annual Net Assets for OKYO Pharma Ltd ADR (2008–2026)
The table below shows the annual net assets of OKYO Pharma Ltd ADR from 2008 to 2026. For live market cap and overall valuation, see OKYO market cap.
| Year | Net Assets | Change |
|---|---|---|
| 2026-03-31 | $12.34 Million | +322.27% |
| 2025-03-31 | $-5.55 Million | +5.61% |
| 2024-03-31 | $-5.88 Million | -186.36% |
| 2023-03-31 | $-2.05 Million | -169.66% |
| 2022-03-31 | $2.95 Million | -44.59% |
| 2021-03-31 | $5.32 Million | +3905.04% |
| 2020-03-31 | $-139.80K | -141.96% |
| 2019-03-31 | $333.14K | -82.62% |
| 2018-03-31 | $1.92 Million | -93.03% |
| 2017-03-31 | $27.50 Million | -14.08% |
| 2016-03-31 | $32.00 Million | -5.59% |
| 2015-03-31 | $33.90 Million | -27.82% |
| 2014-03-31 | $46.96 Million | +4.32% |
| 2013-03-31 | $45.02 Million | +8.83% |
| 2012-03-31 | $41.36 Million | +158.33% |
| 2011-03-31 | $16.01 Million | -70.38% |
| 2010-03-31 | $54.05 Million | +41.57% |
| 2009-03-31 | $38.18 Million | +39.06% |
| 2008-03-31 | $27.46 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to OKYO Pharma Ltd ADR's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 14899700854.0% over the analyzed period, potentially due to dividend distributions or operating losses.
OKYO Pharma Ltd ADR Net Assets Breakdown (March 2026)
OKYO Pharma Ltd ADR net assets breakdown by equity component as of March 2026.
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $173.56 Million | 1407.03% |
| Other Comprehensive Income | $-12.13 Million | -98.33% |
| Other Components | $2.88 Million | 23.33% |
| Total Equity | $12.34 Million | 100.00% |
OKYO Pharma Ltd ADR Competitors by Market Cap
The table below lists competitors of OKYO Pharma Ltd ADR ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Ta Yih Industrial Co Ltd
TW:1521
|
$59.80 Million |
|
Soke Degirmencilik AS
IS:SOKE
|
$59.82 Million |
|
Euro India Fresh Foods Limited
NSE:EIFFL
|
$59.82 Million |
|
Sunview Group Bhd
KLSE:0262
|
$59.83 Million |
|
GreenMobility A/S
CO:GREENM
|
$59.80 Million |
|
OFCO Industrial
TWO:5011
|
$59.79 Million |
|
Gipta Ofis Kirtasiye ve Promosyon Ãrünleri Imalat Sanayi A.S.
IS:GIPTA
|
$59.78 Million |
|
Jia Wei Lifestyle Inc
TW:3557
|
$59.77 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in OKYO Pharma Ltd ADR's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2025 to 2026, total equity changed from -5,549,829 to 12,335,139, a change of 17,884,968.
- Net loss of 8,949,657 reduced equity.
- New share issuances of 25,023,336 increased equity.
- Other comprehensive income decreased equity by 2,887,702.
- Other factors increased equity by 4,698,991.
Equity Change Factors (2025 to 2026)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-8.95 Million | -72.55% |
| Share Issuances | $25.02 Million | +202.86% |
| Other Comprehensive Income | $-2.89 Million | -23.41% |
| Other Changes | $4.70 Million | +38.09% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares OKYO Pharma Ltd ADR's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 4.82x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 3.22x to 4.82x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2008-03-31 | $0.49 | $1.59 | x |
| 2009-03-31 | $1.27 | $1.59 | x |
| 2010-03-31 | $12.62 | $1.59 | x |
| 2011-03-31 | $3.74 | $1.59 | x |
| 2012-03-31 | $9.65 | $1.59 | x |
| 2013-03-31 | $10.16 | $1.59 | x |
| 2014-03-31 | $10.14 | $1.59 | x |
| 2015-03-31 | $5.41 | $1.59 | x |
| 2016-03-31 | $5.46 | $1.59 | x |
| 2017-03-31 | $4.69 | $1.59 | x |
| 2018-03-31 | $0.33 | $1.59 | x |
| 2019-03-31 | $0.04 | $1.59 | x |
| 2020-03-31 | $-0.02 | $1.59 | x |
| 2021-03-31 | $0.51 | $1.59 | x |
| 2022-03-31 | $0.20 | $1.59 | x |
| 2023-03-31 | $-0.09 | $1.59 | x |
| 2024-03-31 | $-0.20 | $1.59 | x |
| 2025-03-31 | $-0.14 | $1.59 | x |
| 2026-03-31 | $0.33 | $1.59 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently OKYO Pharma Ltd ADR utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -72.55%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.70x
- Recent ROE (-72.55%) is above the historical average (-173.97%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2008 | -10.83% | 0.00% | 0.00x | 1.01x | $-5.72 Million |
| 2009 | 37.54% | 0.00% | 0.00x | 1.00x | $10.52 Million |
| 2010 | 23.44% | 0.00% | 0.00x | 1.00x | $7.27 Million |
| 2011 | -10.10% | 0.00% | 0.00x | 1.00x | $-3.22 Million |
| 2012 | -11.62% | 0.00% | 0.00x | 1.02x | $-8.94 Million |
| 2013 | -10.75% | 0.00% | 0.00x | 1.00x | $-9.34 Million |
| 2014 | -29.70% | 0.00% | 0.00x | 1.01x | $-18.64 Million |
| 2015 | -24.35% | 0.00% | 0.00x | 1.00x | $-11.64 Million |
| 2016 | -2.56% | 0.00% | 0.00x | 1.01x | $-4.02 Million |
| 2017 | -0.88% | 0.00% | 0.00x | 1.01x | $-2.99 Million |
| 2018 | -1476.35% | 0.00% | 0.00x | 1.05x | $-28.49 Million |
| 2019 | -1469.36% | 0.00% | 0.00x | 2.28x | $-4.93 Million |
| 2020 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.53 Million |
| 2021 | -63.05% | 0.00% | 0.00x | 1.33x | $-3.89 Million |
| 2022 | -184.26% | 0.00% | 0.00x | 1.46x | $-5.73 Million |
| 2023 | 0.00% | 0.00% | 0.00x | 0.00x | $-13.07 Million |
| 2024 | 0.00% | 0.00% | 0.00x | 0.00x | $-16.24 Million |
| 2025 | 0.00% | 0.00% | 0.00x | 0.00x | $-4.15 Million |
| 2026 | -72.55% | 0.00% | 0.00x | 1.70x | $-10.18 Million |
Industry Comparison
This section compares OKYO Pharma Ltd ADR's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $154,916,114
- Average return on equity (ROE) among peers: -15.75%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| OKYO Pharma Ltd ADR (OKYO) | $12.34 Million | -10.83% | 0.70x | $59.80 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $26.78 Million |
| Abcellera Biologics Inc (ABCL) | $1.06 Billion | -15.42% | 0.29x | $3.53 Billion |
| Abeona Therapeutics Inc (ABEO) | $-5.83 Million | 0.00% | 0.00x | $243.03 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $225.18 Million | -44.68% | 0.02x | $16.93 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $1.41 Billion |
| Arbutus Biopharma Corp (ABUS) | $40.92 Million | 73.18% | 0.29x | $768.65 Million |
| ABVC Biopharma Inc (ABVC) | $29.08K | -111.02% | 1.35x | $26.26 Million |
| Abivax SA American Depositary Shares (ABVX) | $34.02 Million | -17.32% | 0.13x | $7.74 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $182.13 Million | -20.84% | 0.04x | $3.54 Billion |
About OKYO Pharma Ltd ADR
OKYO Pharma Limited, a clinical-stage biopharmaceutical company, develops therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead clinical product candidate is urcosimod, which is in Phase II clinical trials for the treatment of dry eye disease; in Phase II clinical trial to treat neuropathic corneal pain; and is in preclinical trial to t… Read more